2018 Cotellic (cobimetinib; Exelixis/Roche) Drug Analysis - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Cotellic" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. Cotellic specifically binds to and inhibits the catalytic activity of MEK, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation. In preclinical studies, oral dosing of Cotellic resulted in potent and sustained inhibition of MEK in RAS or BRAF mutant tumor models. Cotellic is being developed by Roche under a collaboration agreement with Exelixis.

Key Topics Covered:

Product Profiles

Cotellic: Colorectal cancer (CRC)

Cotellic: Melanoma

List of Figures

Figure 1: Cotellic for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Cotellic for colorectal cancer

Figure 3: Drug assessment summary of Cotellic for colorectal cancer

Figure 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25

Figure 5: Cotellic in melanoma - SWOT analysis

Figure 6: Drug assessment summary of Cotellic for melanoma

Figure 7: Drug assessment summary of Cotellic for melanoma

List of Tables

Table 1: Cotellic drug profile

Table 2: Cotellic Phase III trial in colorectal cancer

Table 3: Cotellic early-phase data in colorectal cancer

Table 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25

Table 5: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25

Table 6: Cotellic drug profile

Table 7: Cotellic pivotal trial data in melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xvv8dk/2018_cotellic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Skin Cancer Drugs